ARTICLE | Company News
Adenosine cardiovascular, inflammation news
July 18, 2005 7:00 AM UTC
Adenosine is seeking strategic alternatives, including a sale of the company. CIBC is advising Adenosine. The company's lead compound is ATL146e, a coronary vasodilator that is in Phase III testing fo...